MATH+ Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale

February 2022 in “ Journal of Clinical Medicine Research ”

Pierre Kory, G. Umberto Meduri, José Iglesias, Joseph Varón, Flavio Cadegiani, Paul E. Marik

Studysummary This review discusses the development of the MATH+ treatment protocol for COVID-19 patients, detailing its scientific and clinical rationale, but reports no new experimental findings.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The "MATH+" protocol was developed by the Front-Line COVID-19 Critical Care Alliance in response to high mortality rates and prolonged mechanical ventilation durations in COVID-19 patients with acute respiratory failure. This protocol included the use of methylprednisolone, ascorbic acid, thiamine, heparin, and non-antiviral co-interventions, diverging from the initial global recommendation of "supportive care only." The protocol was based on clinical observations and emerging data from early outbreak areas, and it aimed to improve outcomes by addressing the inflammatory and coagulopathic aspects of COVID-19. The manuscript provided a detailed review of the scientific and clinical rationale for each component of the MATH+ protocol, supported by various studies on viral syndromes and COVID-19.

View this study on jocmr.org →

Discuss this study in the Community →

Research cited in this study

14 / 14 results

Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial

research Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial

19 citations , December 2021 in “Cureus”

This study found that proxalutamide significantly increased recovery rates, reduced mortality, and shortened hospital stays in hospitalized COVID-19 patients across different regions in Brazil.

research SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism

50 citations , November 2021 in “Viruses”

This study observed that in vitro exposure to dihydrotestosterone worsened COVID-19 spike protein-induced endothelial injury, while spironolactone showed potential in reducing this effect, suggesting a rationale for further evaluation in treating COVID-19.

Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide

research Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide

5 citations , July 2021 in “medRxiv (Cold Spring Harbor Laboratory)”

This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.

Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

42 citations , July 2021 in “Frontiers in Medicine”

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – An Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

research Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – An Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

5 citations , July 2021 in “bioRxiv (Cold Spring Harbor Laboratory)”

This study found that a 14-day treatment with proxalutamide significantly reduced the 28-day mortality rate in hospitalized COVID-19 patients compared to placebo, with greater benefits observed among those who adhered to the treatment.

Finasteride in Hospitalized Adult Males with COVID-19: A Risk Factor for Severity or an Adjunct Treatment - A Randomized Controlled Clinical Trial

research Finasteride in Hospitalized Adult Males with COVID-19: A Risk Factor for Severity or an Adjunct Treatment - A Randomized Controlled Clinical Trial

8 citations , April 2021 in “Medical journal of the Islamic Republic of Iran”

This study found that a short course of finasteride improved oxygen saturation but had no significant impact on mortality rate or length of hospital stay in older male COVID-19 pneumonia patients.

research Alopecia and Severity of COVID-19: A Cross-Sectional Study in Peru

4 citations , March 2021 in “Le infezioni in medicina”

This study found that male COVID-19 patients with androgenic alopecia at a Peruvian hospital were more likely to experience moderate to severe symptoms compared to those without alopecia.

research Expression of Concern: Potential Risk for Developing Severe COVID-19 Disease Among Anabolic Steroid Users

21 citations , February 2021 in “BMJ case reports”

This case study potentially links the use of anabolic steroids to increased severity of COVID-19 in a healthy 28-year-old man, with marked symptom improvement following treatment with proxalutamide.

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

41 citations , February 2021 in “Cureus”

This study found that in males with mild COVID-19, treatment with dutasteride, along with standard therapy, may reduce viral shedding and inflammation compared to placebo.

research Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19

29 citations , October 2020 in “Journal of the European Academy of Dermatology and Venereology”

This article is a discussion piece that examines the clinical symptoms of hyperandrogenic women with COVID-19, without reporting new research findings.

Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients

research Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients

26 citations , September 2020 in “Journal of the European Academy of Dermatology and Venereology”

This publication is a letter discussing the association between an androgen receptor genetic variant and COVID-19 disease severity in hospitalized male patients, but it reports no new research results.

Male Balding as a Major Risk Factor for Severe COVID-19: A Possible Role for Targeting Androgens and Transmembrane Protease Serine 2 to Protect Vulnerable Individuals

research Male Balding as a Major Risk Factor for Severe COVID-19: A Possible Role for Targeting Androgens and Transmembrane Protease Serine 2 to Protect Vulnerable Individuals

6 citations , September 2020 in “Journal of The American Academy of Dermatology”

This letter discusses how severe baldness in men is associated with higher risk of severe COVID-19, and highlights research suggesting antiandrogen medications may improve outcomes.

research Male Balding Is a Major Risk Factor for Severe COVID-19

29 citations , July 2020 in “Journal of The American Academy of Dermatology”

In this study, researchers found that severe androgenic alopecia in hospitalized men was associated with a higher likelihood of testing positive for COVID-19.

research Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign'

119 citations , May 2020 in “Journal of The American Academy of Dermatology”

This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.